Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy
Authors:ID Vrankar, Martina (Author)
ID Stanič, Karmen (Author)
Files:URL URL - Source URL, visit https://content.sciendo.com/view/journals/raon/52/3/article-p281.xml
 
.pdf PDF - Presentation file, download (500,20 KB)
MD5: 258A46BB0F281F730951D019F87BF34B
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Standard treatment for patients with inoperable locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Five-year overall survival rates range between 15 and 25%, while long term survival data are rarely reported. Patients and methods A total of 102 patients with stage III NSCLC treated between September 2005 and November 2010 with induction chemotherapy and CCRT were included in this long term survival analysis. All patients were tested for PD-L1 status and expression of PD-L1 was correlated with overall survival (OS), progression free survival (PFS) and toxicities. Results The median OS of all patients was 24.8 months (95% CI 18.7 to 31.0) with 10 year-survival rate of 11.2%. The median OS of patients with PD-L1 expression was 12.1 months (95% CI 0.1 to 26.2), while in patients with negative or unknown PD-L1 status was significantly longer, 25.2 months (95% CI 18.9 to 31.6), p = 0.005. The median PFS of all patients was 16.4 months (95% CI 13.0 to 19.9). PFS of patients with PD-L1 expression was 10.1 months (95% CI 0.1 to 20.4) and in patients with negative or unknown PD-L1 status was 17.9 months (95% CI 14.2 to 21.7), p = 0.003. Conclusions 10-year overall survival of stage III NSCLC patients after CCRT is 11.2%. PFS and OS differ with regard to PD-L1 status and are significantly shorter for patients with PD-L1 expression. New treatment with check-point inhibitors combined with RT therefore seems reasonable strategy to improve these results.
Keywords:NSCLC, non-small cell lung cancer, locally advanced, immunotherapy, chemoradiotherapy
Publication status:Published
Publication version:Version of Record
Publication date:01.09.2018
Place of publishing:Ljubljana
Publisher:Association of Radiology and Oncology
Year of publishing:2018
Number of pages:str. 281-288, IV
Numbering:Vol. 52, no. 3
Source:Ljubljana
PID:20.500.12556/DiRROS-19072 New window
UDC:616.2
ISSN on article:1318-2099
DOI:10.1515/raon-2018-0009 New window
COBISS.SI-ID:2855035 New window
Copyright:by Authors
Publication date in DiRROS:10.06.2024
Views:534
Downloads:227
Metadata:XML DC-XML DC-RDF
:
VRANKAR, Martina and STANIČ, Karmen, 2018, Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. Radiology and oncology [online]. 2018. Vol. 52, no. 3, p. 281–288, iv. [Accessed 22 March 2025]. DOI 10.1515/raon-2018-0009. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=19072
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Keywords:nedrobnocelični rak pljuč, lokalno napredovali rak pljuč, kemoradioterapija, imunoterapija


Back